Screener
Vaxcyte, Inc. PCVX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001649094-26-000017
| Line item | March 31,2026 | December 31, 2025 |
|---|---|---|
| Accrued contract manufacturing expenses | 134,704 | 74,654 |
| Accrued expenses | 30,247 | 31,068 |
| Operating lease liabilities — current | 6,085 | 6,124 |
| Total current liabilities | 242,082 | 205,750 |
| Operating lease liabilities — long-term | 110,212 | 111,457 |
| Total liabilities | 352,294 | 317,207 |
| Commitments and contingencies (Note 6) | ||
| Stockholders' Equity |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Vaxcyte, Inc.'s total current liabilities?
- Vaxcyte, Inc. (PCVX) reported total current liabilities of $242.08M in Q1 2026.
- How has Vaxcyte, Inc.'s total current liabilities changed year-over-year?
- Vaxcyte, Inc.'s total current liabilities increased by 149.6% year-over-year, from $97M to $242.08M.
- What is the long-term trend for Vaxcyte, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Vaxcyte, Inc.'s total current liabilities has grown at a 34.4% compound annual growth rate (CAGR), from $46.86M to $205.75M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Vaxcyte, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude